The Switch Study: Why a New Mechanism Demands a New Approach

Because Cobenfy (KarXT) is the first dual M1/M4 muscarinic receptor agonist approved for schizophrenia and its novel mechanism of action is entirely distinct from the dopaminergic and serotonergic mechanisms of existing antipsychotics, Walling explained there was no established framework for cross-titrating patients onto a drug of this type.

Prior clinical trials (EMERGENT-1–3) required patients to wash out of their current medications before initiating Cobenfy, he explained, leaving real-world prescribers without guidance on cross-titration.

To address this, an 8-week, multicenter, randomized, open-label outpatient trial comparing a faster 2-week transition (50% AP dose reduction per week) and a slower 4-week transition (25% AP dose reduction per week) from atypical antipsychotics to Cobenfy, reflecting the range of comfort levels clinicians have shown in practice.

In the next episode, "From Design to Data: What the Switch Study Reveals About Efficacy and Symptom Stability," Walling continues his discussion and highlights how the study design reflects real-world clinical practice and what the primary endpoint and rating scale outcomes revealed about transitioning patients.